-
Catalent Analyst Cites Valuation Concerns In Downgrade
Wednesday, August 28, 2019 - 1:42pm | 442Read More...KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end. The company has taken the necessary steps to gain exposure to the high-growth biologics and gene therapy space, according to the sell-side firm. The Analyst Donald Hooker downgraded Catalent from...
-
FDA Issues Final Guidelines To Make Interchangeable Biosimilars More Easily Available
Monday, May 13, 2019 - 1:15pm | 424Read More...The FDA issued final guidelines Friday concerning the interchangeability of biosimilars with biologics with an intention to make the former easily available to patients, just as how generics are used for branded drugs. What Happened The FDA's latest guidelines outlined the studies a...
-
McKesson Announces Acquisitions That Expands Its Oncology Expertise
Thursday, February 25, 2016 - 1:46pm | 254Read More...McKesson Corporation (NYSE: MCK) announced on Thursday two separate acquisitions to increase its specialty pharmaceutical distribution scale and oncology-focused pharmacy offerings, solutions for manufacturers and payers, and scope of community-based oncology and practice management services....
-
Market Wrap For January 17: Stocks Finish Week With Mixed Results
Friday, January 17, 2014 - 4:40pm | 2758Read More...Stocks traded mostly lower today as investors digested a new set of earnings that were disappointing. A mixed housing data and a consumer sentiment coming in lower than expected was enough to tame the bulls as major indices finished the day mixed. Markets will be closed on Monday for Martin...
-
Top Trending Tickers On StockTwits For January 17
Friday, January 17, 2014 - 10:17am | 637Read More...Here's a look at the top tickers trending on StockTwits.com. Ariad Pharmaceuticals On Friday morning, Ariad Pharmaceuticals (NASDAQ: ARIA) announced the commercial availability of Iclusig for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute...
